3 Questions
The IRMA Il trial evaluated the effectiveness of the angiotensin-II-receptor antagonist irbesartan in preventing the development of diabetic nephropathy in hypertensive patients with type 2 diabetes and persistent microalbuminuria.
True
The IRMA Il trial evaluated the effectiveness of the angiotensin-II-receptor antagonist irbesartan in hypertensive patients with type 1 diabetes and persistent microalbuminuria.
False
The IRMA Il trial focused on the use of irbesartan in normotensive patients with type 2 diabetes.
False
Test your knowledge about the IRMA II trial, which aimed to assess the efficacy of irbesartan in delaying the onset of diabetic nephropathy in hypertensive patients with type 2 diabetes and persistent microalbuminuria.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
